Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06620926
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-28
Brief Title:
Impact of IDH Mutation and Adjuvant Chemoradiotherapy on Survival Outcome in Grade IIIII Astrocytoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Impact of IDH Mutation and Adjuvant Chemoradiotherapy on Survival Outcome in Grade IIIII Astrocytoma
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study looked at a type of brain tumor called astrocytoma and how specific genetic changes like IDH mutations affect patients outcomes Recent studies found that people with IDH-mutated astrocytomas tend to live longer and have better survival rates compared to those without these mutations One reason for this is that IDH-mutated tumors usually grow more slowly and are less aggressive These findings suggest that testing for IDH mutations could help doctors make more personalized treatment plans for patients which may lead to better results However larger studies are needed to confirm these observations the investigators used the Surveillance Epidemiology and End Results SEER database to obtain the data of 811 patients with grade IIIII astrocytoma The data are publicly available and no consent or ethical approval is needed for this study The clinicopathological data of patients including the age gender race IDH status mutantwild astrocytoma type diffuseanaplastic surgery tumor destruction Local excision partial radical total gross resection Surgery NOS radiation Beam radiation Radioactive implants including brachytherapy Radioisotopes Combination of beam with implants or isotopes Radiation NOS method or source not specified chemotherapy vital status and survival months were extracted Patients were sub-grouped according to the IDH type into IDH mutant-type and wild-type with further stratification according to the treatment modality into three groups adjuvant chemotherapy adjuvant radiotherapy and combined adjuvant chemoradiotherapy The Observed survival and cause-specific survival were calculated using SEERstat software version 843 and SPSS version 25 was used for survival analysis Significance was achieved at 005
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None